Scarica l'app Stockscreener
0.46
9.79%
0.041
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Nextcure Inc Borsa (NXTC) Ultime notizie
Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks
NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia
NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan
CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India
NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia
NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India
ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India
H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa
NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
2 Net Current Asset Value Stocks to Consider - GuruFocus.com
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN
NextCure Reports 2024 Financials and Strategic Progress - TipRanks
NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times
NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq
Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan
NextCure Inc. (NXTC) reports earnings - qz.com
Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com
NextCure stock plunges to 52-week low, hits $0.69 - MSN
NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada
Ventia Strengthens Leadership with New Company Secretary Appointment - MSN
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance
Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN
NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World
Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - Chosunbiz
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):